Targeting Protease-Activated Receptors (PARs) to Overcome CNS Inflammation

Acute and more-sustained inflammatory responses are a key component of many neurological disorders, whether of autoimmune, viral, genetic, traumatic or idiopathic origin. Based on preliminary findings in Dr. Scarisbrick's lab, it is hypothesized that elevated levels of secreted serine proteases at sites of neuropathology promote aberrant activation of protease-activated receptors that in turn promote and sustain neuroinflammation, thereby directly or indirectly driving astrogliosis, demyelination and neurodegeneration.

This line of research has resulted in the following patents:

  • US 7,754,216 Method of treating Multiple Sclerosis with Anti-K6 antibody
    Inventors: Isobel Scarisbrick, Moses Rodriguez, Sachiko Blaber and Michael Blaber
  • US 8,530,427 Methods for Modulating Resistance to Apoptosis using KLK6
    Inventors: Isobel Scarisbrick
  • US 2013/0315926 Methods and Materials for Modulating Resistance to Apoptosis
    Inventors: Isobel Scarisbrick

In ongoing projects, the neuroinflammatory and neurodegenerative roles of protease-activated receptors and their mechanism of action are being dissected to determine therapeutic utility for neuroprotection, neural regeneration and restoration of function.